A field vaccine trial in Tanzania demonstrates partial protection against malignant catarrhal fever in cattle by Lankester, F. et al.
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a  b  s  t  r  a  c  t
Malignant  catarrhal  fever  (MCF)  is a fatal  lymphoproliferative  disease  of  cattle  that,  in  East  Africa,
results  from  transmission  of  the  causative  virus,  alcelaphine  herpesvirus  1  (AlHV-1),  from  wildebeest.
A  vaccine  ﬁeld  trial involving  an  attenuated  AlHV-1  virus  vaccine  was  performed  over two  wildebeest
calving  seasons  on  the  Simanjiro  Plain  of  northern  Tanzania.  Each  of  the  two  phases  of  the  ﬁeld  trial
consisted  of  groups  of  50  vaccinated  and  unvaccinated  cattle,  which  were  subsequently  exposed  to  AlHV-1
challenge  by  herding  toward  wildebeest.  Vaccination  resulted  in  the  induction  of virus-speciﬁc  and  virus-
neutralizing  antibodies.  Some  cattle  in  the  unvaccinated  groups  also  developed  virus-speciﬁc  antibody
responses  but only  after  the  start of  the challenge  phase  of  the trial.  PCR of  DNA from  blood  samples
detected  AlHV-1  infection  in  both  groups  of  cattle  but the  frequency  of infection  was  signiﬁcantly  lower
in  the  vaccinated  groups.  Some  infected  animals  showed  clinical  signs  suggestive  of  MCF  but  few  ani-
mals  went  on to  develop  fatal  MCF,  with  similar  numbers  in  vaccinated  and  unvaccinated  groups.  Thisaccine efﬁcacy
anzania
study  demonstrated  a baseline  level  of  MCF-seropositivity  among  cattle  in northern  Tanzania  of  1% and
showed  that  AlHV-1  virus-neutralizing  antibodies  could  be induced  in  Tanzanian  zebu shorthorn  cross
cattle  by  our  attenuated  vaccine,  a correlate  of  protection  in previous  experimental  trials.  The  vaccine
reduced  infection  rates  by  56%  in  cattle exposed  to  wildebeest  but protection  from  fatal  MCF  could  not
be  determined  due  to the low  number  of  fatal  cases.
ublis©  2015  The  Authors.  P
. Introduction
Malignant catarrhal fever (MCF) is an infectious systemic dis-
ase of artiodactyls that is caused by -herpesviruses of the genus
acavirus. The disease occurs following cross-species transmis-
ion from a carrier host that harbours the virus subclinically [30].
wo major epidemiological forms of MCF  exist, deﬁned by the
eservoir species from which the causative -herpesvirus arises:
) wildebeest-associated (WA-MCF) [22] and ii) sheep-associated
SA-MCF) [26]. WA-MCF occurs primarily in sub-Saharan Africa
herever wildebeest come into contact with cattle. The causative
∗ Corresponding author. Tel.: +254 723 982662.
E-mail address: lankesterf@vetmed.wsu.edu (F. Lankester).
ttp://dx.doi.org/10.1016/j.vaccine.2015.12.009
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
pathogen in WA-MCF, alcelaphine herpesvirus-1 (AlHV-1) [22,27],
is excreted principally by wildebeest calves (Connochaetes tauri-
nus) in the three months following the brief annual calving period.
To avoid disease, pastoralists move their cattle from wildebeest
calving grounds, often to more marginal land tens of km away,
at a time of year when the condition of cattle is most vulner-
able. Consequently, the economic costs associated with MCF  in
high-risk areas can be signiﬁcant [3,4,12]. SA-MCF, caused by ovine
herpesvirus-2 (OvHV-2), occurs worldwide wherever sheep and
disease-susceptible animals are in proximity [26]. OvHV-2 is phy-
logenetically related to AlHV-1 with signiﬁcant DNA sequence
identity [9].
Typical clinical signs of WA-MCF or SA-MCF in cattle include
fever, lesions in the oral and nasal mucosa, mucopurulent
nasal discharge, corneal opacities and, frequently, death [18,30].
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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istologically, MCF  is characterized by vasculitis, epithelial damage
nd lymphocytic inﬁltration of tissues [21]. It is currently believed
hat virus-infected T-cells are responsible for MCF pathogenesis,
lthough the speciﬁc mechanisms are not fully resolved [5,32].
Transmission from reservoir hosts to MCF  susceptible animals is
hought to be by aerosol transmission and contact with the virus on
asture. For AlHV-1 MCF, there is recent evidence that wildebeest
lacentae contain virus [13], but its role in the epidemiology of MCF
s not clear [4,29].
There have been several attempts to develop an effective vac-
ine against MCF  [7,23]. Recent success with an attenuated AlHV-1
accine that protected British Holstein-Friesian cattle from exper-
mental intra-nasal challenge with AlHV-1 (mimicking a natural
oute of transmission) [8,17,31] was based on the induction of a
ucosal barrier of virus-neutralizing antibodies in the oro-nasal
haryngeal region [8,31]. This vaccine was effective for six months,
hich should protect cattle during the wildebeest calving season
31]. In this study, the vaccine was tested for the ﬁrst time under
eld trial conditions in northern Tanzania. The trial was timed to
oincide with two wildebeest calving seasons (mid-February), with
ildebeest calves expected to shed AlHV-1 virus until approxi-
ately 3 months of age [20].
. Materials and methods
.1. Study site and baseline serological survey
The study site was the Simanjiro Wildlife Dispersal Area (Siman-
iro Plain), a mixed-use livestock grazing and wildlife dispersal area
0 km east of Tarangire National Park in northern Tanzania (lati-
ude -3.952239, longitude 36.47537) (Fig. 1). Prior to the start of
he trial, MCF  seroprevalence was estimated in cattle herds around
he study site. Herds and cattle were selected at random, with a total
f 362 cattle sampled from 22 herds in four villages within 40 km of
he national park (Fig. 1). Serum samples were heat-treated (56 ◦C,
0 min) to inactivate adventitious pathogens before being shipped
rozen to the Moredun Research Institute, UK, for serological anal-
sis, as described below.
.2. Animals
A total of 200 crossbred Tanzanian shorthorn zebu cattle of
pproximately six months of age were purchased at the local
ukuro primary livestock market. On arrival at the study site (at
east one month before MCF  vaccination), all were ﬁtted with ear
ags, immunized against East Coast fever (ECF) [6,10], and treated
or endo- and ectoparasites (detailed in Supplementary Data 1).
.3. Field trial design
The ﬁeld trial was a blinded randomized controlled trial. Sample
ize calculations indicated that groups of 43 cattle would enable,
ith 95% conﬁdence and a power of 80%, the detection of a decline
n the proportion of exposed animals succumbing to MCF from 30
o 5% [1,19]. To increase the power, groups of 50 vaccinated and 50
nvaccinated animals were used and the trial was carried out twice,
rstly between December 2010 and July 2011 (2011 trial) and sec-
ndly between the same months the following year (2012 trial). In
ach trial, the cattle were randomly divided into a vaccinated group
hat received a prime and, four weeks later, a boost containing the
ttenuated AlHV-1 C500 virus mixed with the adjuvant Emulsigen®20% v/v) administered intramuscularly in the upper neck region,
nd an unvaccinated group that received a mock prime and boost
sing a virus-free Emulsigen® inoculum, as described previously
31]. 34 (2016) 831–838
In each trial, the challenge phase began in mid-February and
lasted until the end of May. During this period, cattle were grazed
as a single herd close to wildebeest and their calves. To estimate
the daily intensity of challenge, a contact index was calculated as
described in Supplementary Data 2.
Clinical signs of disease (ocular/nasal discharge or lesions;
changes in demeanour or appetite) were recorded daily while rectal
body temperatures were recorded every second day, or daily if sick.
Cattle were classiﬁed daily as ‘healthy’, or, if they had temperature
≥39 ◦C or clinical signs as described above, ‘sick’.
Uncoagulated blood and nasal secretion (NS) samples were
collected from all cattle starting at the time of primary inocula-
tion (month zero) and ending six months later. NS samples were
collected using a tampon (Lil-lets®, regular) inserted into one nos-
tril for 10 min. Plasma and buffy coat cells from uncoagulated
blood and NS samples were stored at -20 ◦C. Prior to exporta-
tion to the UK cell-free samples were heat-treated at 56 ◦C for
30 min.
2.4. Pathology and histopathology
In fatal cases, a post-mortem examination was  performed and
tissue samples (kidney, liver, lung and lymph node) collected
and ﬁxed in 10% formalin. Following export to the Moredun
Research Institute (licence: POAO(S)/2011/54), the ﬁxed samples
were embedded in parafﬁn wax and stained with hematoxylin
and eosin. Histopathological examination enabled the pathology
of each case to be summarized as: Category A: MCF  (most organs
contained signiﬁcant numbers of lesions consistent with a diagno-
sis of MCF) [8]; Category B: non-speciﬁc infection, consistent with
MCF  (small number of lesions of mild intensity, without exten-
sive inﬁltration of lymphocytes or clear vasculitis, in one or two
studied organs); or Category C: negative (no signiﬁcant lesions
observed).
2.5. Antibody responses
Plasma and NS antibody responses were measured by
AlHV-1 virus-speciﬁc (ELISA) and virus-neutralizing antibody
(VNA) assays, following previously described protocols [8,31].
MCF-affected cattle can develop virus-speciﬁc but not virus-
neutralizing antibodies, while induction of neutralizing antibodies
in plasma and NS is associated with vaccine-induced protection
[8,31].
ELISA values for each sample were calculated as the difference
between means of positive and negative antigen wells for each
sample dilution. In the baseline serosurvey, positive samples were
deﬁned as those having an ELISA value greater than the cut-off value
(mean plus 3 × standard deviation of all samples). In the vaccine
ﬁeld trial, ELISA values were used to calculate a relative titre for
each test sample, with respect to standard curves of pooled MCF-
positive plasma or NS, with dilutions of 1/20 to 1/6400. ELISA titre
values have been expressed as the reciprocal of the calculated titre
(e.g. 20−6400). Any sample that gave a calculated titre of less than
20 (i.e. below the range of the standard curve) was not considered
positive. VNA analyses were conducted on selected trial cattle at the
time of primary vaccination and at the two-month time point, as
detailed in Supplementary Data 3. Vaccinated cattle were selected
for VNA analysis at random, while all unvaccinated cattle with pos-
itive ELISA titres were tested.
2.6. Detection of viral DNA in bloodViral DNA was  extracted from frozen buffy coat samples using
the ZR Viral DNA KitTM(Zymo Research Coporation, USA) accord-
ing to the manufacturer’s instructions and was  assayed by nested
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attle  are traditionally herded (black solid line) to ﬁnd substitute grazing pastures (
riangles) and seronegative (green circles) in the baseline serological screen are also
CR as described previously [31]. Animals were classiﬁed as AlHV-
 positive if one or more PCR analyses during the challenge phase
ere positive.
.7. Case deﬁnitions
Three case deﬁnitions were used for this trial based on PCR
etection of AlHV-1 DNA, histopathology and clinical signs:
I. Not infected: AlHV-1 DNA was not detected by PCR in any
buffy-coat sample taken during the challenge phase of the
trial.
II. AlHV-1 infected: AlHV-1 DNA was detected by PCR and the
animal survived or, if the animal died, there were no histopatho-
logical lesions indicative of MCF.II. Fatal MCF: the animal died following clinical signs typical
of MCF. AlHV-1 DNA was detected by PCR and post-mortem
histopathological ﬁndings were consistent with MCF  (cate-
gories A and B).o Plain, the wildebeest migration routes (blue dotted line) and the direction that
e area) are indicated. The locations of the herds that tested MCF  seropositive (black
n.
2.8. Statistical analyses
All statistical analyses were performed using the R language for
statistical computing [33]. Linear regression models were used to
assess vaccine safety and to determine whether the results were
consistent between the two phases of the trial. A Pearson corre-
lation coefﬁcient was used to examine the relationship between
virus-speciﬁc and -neutralizing antibody titres. Binomial gener-
alized linear models (GLM) were used to analyse the predictive
effect of (i) antibody titres on survival and (ii) vaccination status
and antibody titres on AlHV-1 infection status.
3. Results
3.1. Baseline seroprevalence surveyOf the 362 cattle sampled during the baseline survey, four cattle
(from three separate herds) were seropositive for MCF, giving an
apparent seroprevalence of 1%. The locations of the tested and MCF
seropositive herds are shown in Fig. 1.
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Fig. 2. Contact between trial cattle and wildebeest calves. Contact index values (calculated as described in Supplementary Data 2) are plotted in 5-day increments from the
start  of the challenge phase.
Table 1
Group speciﬁc (vaccinated and unvaccinated) outcomes of the 2011 and 2012 trials.
Trial Group Clinicala Died Histopathologyb PCRc Case
deﬁnitiond
Unvaccinated,
PCR negative,
seroconvertede
2011 Vaccinated
(n = 50)
39 2 Category A: 2 Pos 10 I. 38
Neg 38 II. 8
NT 2 III. 2
ND 2
2011  Unvaccinated
(n = 50)
46 2 Category A: 1 Pos 22 I. 24 13
Category B: 1 Neg 24 II. 20
NT 4 III. 2
ND 4
2012  Vaccinated
(n = 50)
50 2 Category A: 1 Pos 9 I. 38
Category C: 1 Neg 38 II. 8
NT 3 III. 1
ND 3
2012  Unvaccinated
(n = 50)
49 2 Category B: 2 Pos 19 I. 27 12
Neg 27 II. 17
NT 4 III. 2
ND 4
a Clinical: Number of cattle that were recorded as being sick during the challenge phase.
b Histopathology: Number of fatal cases whose tissues were categorized as: (A) pathology consistent with MCF; (B) pathology consistent with a non-speciﬁc infection and
(C)  no pathology detected.
c PCR: Pos, AlHV-1 DNA detected at one or more time points; Neg, AlHV-1 DNA not detected in any sample; NT = not tested or ambiguous result.
d Case deﬁnition: (I) not infected; (II) AlHV-1 infected; (III), fatal MCF; (ND,) not deﬁned.
e Unvaccinated, PCR negative, seroconverted: Number of unvaccinated cattle that had serological but not PCR evidence of AlHV-1 infection.
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l.2. Vaccine safety
In the 2011 trial, cattle were monitored closely during the two
eeks following primary vaccination for signs of ill health. Dur-
ng this two-week period 7% of cattle were recorded as ‘sick’,
ith the percentage the same in the vaccinated and unvaccinated
roups. As regression analysis indicated that vaccination status
as not a predictor of daily body temperature during this period
p = 0.93, F = 0.008, df = 698), the mild sickness was considered unre-
ated to vaccination. Further, there were no adverse sub-cutaneousreactions at the site of inoculation. We conclude that the vaccine is
safe for use in Tanzanian shorthorn zebu cattle.
3.3. Contact between wildebeest calves and trial cattle
The data used to calculate the daily contact index are shown in
Supplementary Data 2 and the temporal contact pattern is shown in
Fig. 2. Early in the challenge phase few wildebeest calves were born
and the index was  low (< 3000). Thereafter, the number of calves in
contact increased sharply, to a peak of 142 between day 26 and 30,
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contact index > 23,000). Variation in calf numbers appears to drive
he pattern of contact up to day 50, after which calf numbers reduce
o below 100 and the increase in contact index is driven equally by
ncreasing contact duration and proximity. This might reﬂect either
hat the wildebeest were becoming habituated to cattle grazing
lose by or that the Maasai herders, who had been instructed to
raze the trial cattle as close as possible to the wildebeest, were
mproving their herding skills. Maximum contact index (40,824)
ccurred between days 81 and 85. The wildebeest began to move
way from the Simanjiro Plain around day 100 and the daily contact
ndex decreased to zero by day 106 (Fig. 2).
.4. Field trial outcomes
A complete summary of the individual cattle outcomes from the
eld trial is shown in Supplementary Data 1.
.5. Clinical, mortality and histopathological data
A summary of the outcomes of the 2011 and 2012 trials is shown
n Table 1. Across both trials, three vaccinated and four unvac-
inated cattle died after developing clinical signs consistent with
CF. Histopathological examination indicated that all seven cattle
ad pathology consistent with MCF  (Categories A and B) and were
CR positive for AlHV-1 DNA. An additional vaccinated animal died
eracutely in the 2012 trial with symptoms typical of black-quarter
isease, a bacterial infection most commonly caused by Clostridium
hauvoei (acute lameness, crepitus and sudden death). There were
o lesions observed on histopathology (Category C) but PCR analy-
is performed on kidney and mediastinal lymph nodes was positive
or AlHV-1 DNA.
.6. Analysis of AlHV-1 infection by PCR
AlHV-1 DNA was assayed at three time points during the chal-
enge phase of the trial, following the period of highest contact with
ildebeest [21] (see Supplementary Data 2 and 4). Viral DNA was
ot detected in any sample collected prior to virus challenge. PCR
esults are summarized by vaccination group in Table 1 and Fig. 3. In
otal, 45% of unvaccinated cattle became AlHV-1 infected compared
ith 20% of vaccinated cattle. Modeling indicated that vaccination
tatus was a signiﬁcant predictor of infection with unvaccinated
nimals more likely to be infected (p = 0.0004, Z = -3.5, df = 185).
.7. Case deﬁnitions and vaccine efﬁcacy
The clinical, mortality, histopathology and PCR data allowed
very animal to be allocated to one of three case deﬁnitions sum-
arized in Table 1. The numbers in each category did not differ
igniﬁcantly between the 2011 and 2012 trials (p = 0.54, F = 0.37,
f = 185). In total, 19 of 95 vaccinated cattle became infected with
lHV-1, of which three developed fatal MCF. In the unvaccinated
roups, 41 of 92 cattle became infected and four developed fatal
CF. One vaccinated animal was PCR positive for AlHV-1 but died
eracutely of suspected black quarter. This was assigned to Case
eﬁnition II (AlHV-1 infected) due to the pathognomonic clinical
igns of black quarter and the lack of MCF-speciﬁc histopathology.
Vaccine efﬁcacy was calculated with respect to preventing
lHV-1 infection (as deﬁned by PCR) according to published meth-
ds [11,15] (Supplementary Data 5). Vaccine efﬁcacy was 56% for
reventing infection with AlHV-1. We  did not calculate efﬁcacy at
reventing fatal MCF  as the number of fatal cases in each group was
imilar.
To investigate the longer-term consequences of non-fatal infec-
ions, including possible recrudescence, 27 cattle from the 2011
rial were kept until the end of the 2012 trial. Despite 13 cattle 34 (2016) 831–838 835
having PCR or serological evidence of non-fatal AlHV-1 infection,
none showed any signs of MCF  during this extended period.
3.8. Serological analysis
The NS and plasma AlHV-1-speciﬁc (ELISA) antibody titres for
all animals tested at each monthly time point are shown in Supple-
mentary Data 1. The geometric mean NS and plasma ELISA titres for
the vaccinated and unvaccinated groups are shown in Fig. 4. All vac-
cinated animals had positive plasma and NS  ELISA titres with mean
plasma titres peaking two months after primary immunization. NS
ELISA titres also peaked two months after primary immunization in
the 2012 trial but, unlike the plasma titres, showed a signiﬁcantly
lower response in the 2011 trial (p < 2.2 × 10−16, F = 173.2, df = 98).
During the challenge phase, 40 of the 100 unvaccinated animals
had at least one plasma or NS sample return a seropositive result
suggestive of exposure to AlHV-1. Despite this, the mean plasma
and NS ELISA titres of unvaccinated animals were essentially zero
throughout both the 2011 and 2012 trials.
The full data set from the plasma and NS VNA analysis is shown
in Supplementary Data 1. All available samples from vaccinated cat-
tle (94) were tested for NS VNA at the point of peak ELISA response,
while a subset of these (23) was  also tested for plasma VNA at the
same point. All unvaccinated cattle with MCF-speciﬁc ELISA titre
>20 were tested for VNA in both NS and plasma. At peak serolog-
ical response, 31 and 76% of vaccinated cattle from the 2011 and
2012 trials, respectively, had positive NS VNA titres. No unvacci-
nated cattle in either trial produced VNA. The geometric mean NS
VNA titres of vaccinated cattle in the 2011 trial were signiﬁcantly
lower than the 2012 trial titres (p = 3.5 × 10-5, F = 18.9, df = 92).
3.9. The effect of antibody titre on infection status
At peak serological response, ELISA and VNA titres in vaccinated
cattle were signiﬁcantly correlated in plasma (p < 0.02, r = 0.25,
t = 2.4, df = 92) and NS (p < 1.0 × 10−6, r = 0.51, t = 5.6, df = 92). Fig. 5A
illustrates the correlation and how the titres of infected and unin-
fected cattle were distributed. Although vaccination status, and
thus presence of ELISA and VNA antibodies, has been shown (above)
to be a strong predictor of infection status as determined by PCR,
modeling indicated that the magnitude of ELISA and VNA titres
did not have a signiﬁcant inﬂuence on whether vaccinated cattle
became infected (p > 0.3; Fig. 5B). However the presence of VNA
antibodies in NS of vaccinated cattle was  weakly associated with
protection from infection in vaccinated cattle (p = 0.07).
3.10. Infection status determined by post-challenge
seroconversion
In unvaccinated cattle seroconversion is an indicator of AlHV-1
infection. This can be used in combination with PCR results to deter-
mine the proportion of unvaccinated cattle that became infected
during challenge (Supplementary Data 1). Of 97 initially seroneg-
ative unvaccinated cattle, 40 seroconverted during the challenge
phase, while a further 26 remained seronegative but were PCR
positive (Table 1). In total, 66 out of 97 (68%) unvaccinated cattle
showed evidence of post-challenge infection, of which four died of
MCF. The proportion of infected unvaccinated cattle that died of
MCF  was 6%.
4. DiscussionThis paper describes the ﬁrst ﬁeld trial of a vaccine for
wildebeest-associated malignant catarrhal fever, previously tested
using experimentally challenged British Holstein-Friesian cattle
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011  and 2012 trials are plotted as geometric means for each month. P = primary va
8,17,31]. The clinical data from this trial indicated that the attenu-
ted virus vaccine formulation was well tolerated, with no evidence
f adverse effects. Importantly, vaccinated cattle were more than
wice as likely as unvaccinated cattle to remain uninfected with
CF  virus transmitted naturally from wildebeest. Due to the
nexpectedly low number of fatal MCF  cases, we cannot draw con-
lusions regarding the vaccine’s efﬁcacy at reducing lethal MCF. As
e are not aware of any herpesvirus vaccines that prevent infec-
ion and the establishment of latency, we consider the proportion
f vaccinated animals, in both laboratory trials (70 [8] and 81%
31]) and this ﬁeld trial (80%), that did not become infected in
he face of intense challenge as a promising indication for vac-
ine improvement strategies. Initial work to improve the response
nduced by the current vaccine strategy by the inclusion of spe-
iﬁc toll-like receptor agonists with the adjuvant has been tested
n other vaccine trials [17,38]. However, any further improve-
ent of this vaccine should be done in the context of a natural
hallenge system that will demonstrate the beneﬁts for livestock
eepers.sponses in vaccinated (dashed line) and unvaccinated (solid line) animals from the
tion, B = booster vaccination and C = beginning of challenge phase.
The serological analysis indicated that the vaccine was  effective
at eliciting a virus-speciﬁc immune response in all vaccinated cat-
tle. ELISA titres peaked two  months after primary inoculation. The
NS results, however, varied between the trials, with both ELISA and
VNA titres being signiﬁcantly lower in 2011. As the plasma ELISA
titres from both trials were similar (Fig. 4), it is possible that these
results were caused by a sample processing issue in the 2011 NS
samples rather than a failure of the vaccine itself.
The moderately strong correlation between the ELISA and
VNA titres in NS and plasma samples (Fig. 5A) was expected,
with all cattle that exhibited high VNA titres also having a high
ELISA titre. There were, however, some cattle that, despite hav-
ing relatively high ELISA titres, had low or zero VNA titres. It
is unclear why  these cattle failed to produce neutralizing anti-
bodies but host genetic or immunological factors could focus
virus-speciﬁc immune responses on antigens or epitopes that
were non-neutralizing. Indeed, two AlHV-1 capsid proteins, which
are unlikely to be neutralizing antigens, are strongly recognized
by AlHV-1 vaccinated or infected cattle sera [2]. Analysis of NS
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indicate  the regression line and associated 95% conﬁdence interval (r = correlation coefﬁcient). Subsequent infection status is shown as follows: grey triangles = PCR positive
cases;  black circles = PCR negative cases. (B) Nasal secretion and plasma geometric mean ELISA titres from vaccinated cattle are plotted for each month during the 2011 and
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NA data from the vaccinated cattle showed that the correla-
ion between the presence of VNA antibodies and protection from
nfection approached, but did not achieve, statistical signiﬁcance
p < 0.07). This is illustrated in Fig. 5A, where nine of 60 cattle with
NA titre >10 were infected (grey triangles on the right of the ﬁg-
re). This lack of a signiﬁcant association may  indicate that the
nduction of mucosal VNA is not as strong a correlate of protec-
ion as previously thought and that other aspects of the immune
esponse induced by vaccination may  also contribute to protection
rom MCF. It may  also reﬂect differences in the mode of challenge
etween this trial and previous trials where the source of virus, the
ose and the timing of challenge were all controlled.
WA-MCF is reported to have a ‘case-fatality rate’ of between
6 and 100% [3,22,28]. However, these reports may  be based
n observed progression of clinical MCF  cases in the absence of
apability to estimate sub-clinical infection rates. The baseline
eroprevalence analysis of cattle provided preliminary evidence
hat non-fatal AlHV-1 infections do occur. Similarly, among the
rial cattle, four animals had low ELISA titres in plasma at day zero,
lthough none had detectable AlHV-1 DNA at any time point tested.
wo of these cattle were subsequently vaccinated and developed
igh ELISA and VNA titres, while the other two were unvaccinated
nd had low positive ELISA titres but no VNA titre (Supplementary
ata 1). It is unclear whether this apparent pre-exposure to AlHV-1
nﬂuenced the outcome of these cattle to subsequent challenge. PCR
nd serological evidence indicated that 68% of unvaccinated cattle
ecame infected during the challenge phase of the trial, however
nly 6% of infected cattle developed fatal MCF. This high frequency
f non-fatal infections could reﬂect the true range of outcomes fol-
owing AlHV-1 infection. Indeed, in SA-MCF, non-fatal infections
ave been reported [14,16].
The East Coast fever vaccination, administered to all trial
attle before the MCF  vaccine, may  have inﬂuenced the post-
nfection outcomes seen in the trial. The ECF vaccine is thought
o induce a cell-mediated immune response that suppresses the6). P = primary vaccination, B = booster vaccination and C = beginning of challenge
proliferation of CD8 T-cells [6,24]. The cell biology and pathogenesis
of MCF  are not fully understood, but the associated indiscrimi-
nate tissue damage is thought to involve virus-infected CD8 T- cells
[5,9,32,34]. Thus, the immuno-modulating effects of the ECF vac-
cination might provide some protection from fatal MCF  pathology
among all trial cattle and warrants further study.
This trial also provided further insights into natural AlHV-1
infection. For example, most PCR-positive samples came from a
time point close to challenge day 70 in both trials. The estimated
incubation period for MCF  is about 21 days [21], indicating an
infection window close to day 49, which coincides with a peak in
wildebeest contact index (Fig. 2). These results show that herding
cattle close to wildebeest calves of less than three months of age
does expose them to AlHV-1 and underscores the accuracy of the
timing of the traditional Maasai disease avoidance strategy.
Conservationists have often been concerned that an effective
MCF vaccine may  result in large-scale, unsustainable shifts in
livestock grazing that could cause environmental damage in the
important wildlife dispersal areas adjacent to parks and game
reserves. However, the partial (56%) protection provided by this
vaccine is probably insufﬁcient for pastoralists to risk changing
traditional avoidance strategies to graze cattle in productive lands
alongside wildebeest during the calving season. Nonetheless, even
partial protection would still be of value to protect animals that can-
not be moved, for example, where some of the herd remain at the
permanent family boma to provide milk for women and children
attending school [12], or where land-use changes make traditional
disease avoidance strategies difﬁcult [25,37]. A partially protective
vaccine may  therefore offer a feasible solution to some of the cur-
rent land-use challenges and conﬂicts, providing some protection
to valuable livestock where avoidance strategies are not possible,
but with less risk of potentially damaging environmental conse-
quences. More widely, the vaccine could also play a role around
the world in disease prevention strategies where cattle live in close
proximity to zoological gardens housing wildebeest calves [35,36].
8 accine
5
z
S
F
1
i
a
a
O
P
A
D
o
i
n
B
j
O
t
(
A
t
0
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
tional Livestock Research Institute; 2015.38 F. Lankester et al. / V
. Research and ethical clearance
The research was carried out with the approval of the Tan-
anian Wildlife Research Institute (TAWIRI), the Commission for
cience and Technology (COSTECH, Tanzania) and the Tanzania
ood and Drug Administration (permit nos. 2011-213-ER-2005-
41 and 2012-318-ER-2005-141). The vaccination trial, including
mmunization, sampling, clinical scoring and criteria for euthanasia
fter onset of MCF  [31], followed protocols established during tri-
ls at the Moredun Research Institute, UK compliant with Home
fﬁce of Great Britain and Northern Ireland ‘Animals (Scientiﬁc
rocedures) Act 1986′ under project licence PPL 60/3839.
cknowledgements
This work was supported by the Scottish Government, the
epartment for International Development and the Biotechnol-
gy and Biological Sciences Research Council under the CIDLID
nitiative (Control of Infectious Diseases of Livestock for Inter-
ational Development) grants BB/H008950/1, BB/H009116/1 and
B/H009302/1. We  are grateful for the cooperation of the Siman-
iro Development Trust, the people of Emboreet Village, Dr. Moses
le Neselle and Dr. Imam Mzimbiri for their cooperation and to
he Nelson Mandela Africa Institution for Science and Technology
Arusha, Tanzania) for access to their laboratory and equipment.
Conﬂict of interest statement:  None.
ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.vaccine.2015.12.
09.
eferences
[1] Barnard BJH, van de Pypekamp HE. Wildebeest-derived malignant catarrhal
fever: unusual epidemiology in South Africa. Onderstepoort J Vet Res
1988;55:69–71.
[2] Bartley K, Deane D, Percival A, Dry IR, Grant DM,  Inglis NF, et al. Identiﬁcation
of  immuno-reactive capsid proteins of malignant catarrhal fever viruses. Vet.
Microbiol 2014;173(1–2):17–26. Available at: http://www.ncbi.nlm.nih.gov/
pubmed/25091530 [Accessed 28 November 2014].
[3]  Bedelian C, Nkedianye D, Herrero M.  Maasai perception of the impact and inci-
dence of malignant catarrhal fever (MCF) in southern Kenya. Prev Vet Med
2007;78(3):296–316.
[4] Cleaveland S, Kusiluka L, Ole Kuwai J, Bell C, Kazwala R. Assessing the impact
of  malignant catarrhal fever in Ngorongoro District, Tanzania, Cook, A., 2015.
Wildlife-livestock-human interface: recognising drivers of disease. In Livestock
Systems and Environment Monthly Seminar Series. Nairobi: International Live-
stock Research Institute; 2001.
[5] Dewals B, Boudry C, Farnir F, Drion PV, Vanderplasschen A. Malignant
catarrhal fever induced by alcelaphine herpesvirus 1 is associated
with proliferation of CD8+ T cells supporting a latent infection. PloS
one 2008;3(2):e1627. Available at: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=2229840&tool=pmcentrez&rendertype=abstract
[Accessed 27 March 2013].
[6] Di Giulio G, Lynen G, Morzaria S, Oura C, Bishop R. Live immunization against
East Coast fever-current status. Trends Parasitol 2008;25(2):85–92. Available
at: http://www.ncbi.nlm.nih.gov/pubmed/19135416 [Accessed 10 June 2014].
[7]  Edington N, Plowright W.  The protection of rabbits against the herpesvirus of
malignant catarrhal fever by inactivated vaccines. Res Vet Sci 1980;28:384–6.
[8] Haig DM,  Grant D, Deane D, Campbell I, Thomson J, Jepson C, et al. An
immunisation strategy for the protection of cattle against alcelaphine
herpesvirus-1-induced malignant catarrhal fever. Vaccine 2008;26(35):
4461–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18601965
[Accessed 27 March 2013].
[9] Hart J, Ackermann M,  Jayawardane G, Russell G, Haig DM,  Reid H, et al.
Complete sequence and analysis of the ovine herpesvirus 2 genome. J
Gen Virol 2007;88(Pt 1):28–39. Available at: http://www.ncbi.nlm.nih.gov/
pubmed/17170433 [Accessed 27 March 2013].10] Homewood K, Trench P, Randall S, Lynen G, Bishop B. Livestock health
and socio-economic impacts of a veterinary intervention in Maasai-
land: infection-and-treatment vaccine against East Coast fever. Agric Syst
2006;89(2–3):248–71. Available at: http://linkinghub.elsevier.com/retrieve/
pii/S0308521X05001903 [Accessed 6 June 2013].
[ 34 (2016) 831–838
11] Knight-Jones TJD, Edmond K, Gubbins S, Paton DJ. Veterinary and human vac-
cine evaluation methods. Proc Biol Sci/Royal Soc 2014;281(1784):20132839.
Available at: http://www.ncbi.nlm.nih.gov/pubmed/24741009.
12] Lankester F, Lugelo A, Kazwala R, Keyyu J, Cleaveland S, Yoder J. The eco-
nomic impact of malignant catarrhal fever on pastoralist livelihoods. PloS one
2015;10(1):1–18.
13] Lankester FJ, Lugelo A, Mnyambwa N, Ndabigaye A, Keyyu J, Kazwala R, et al.
Alcelaphine herpesvirus-1 (malignant catarrhal fever virus) in wildebeest pla-
centa: genetic variation of ORF50 and A9.5 alleles. PloS One 2015;10(5).
14] Moore DA, Kohrs P, Baszler T, Faux C, Sathre P, Wenz JR, et al. Outbreak of malig-
nant  catarrhal fever among cattle associated with a state livestock exhibition. J
Am  Vet Med  Assoc 2010;237(1):87–92. Available at: http://www.ncbi.nlm.nih.
gov/pubmed/20590500.
15] Orensteini WA,  Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, et al. Field
evaluation of vaccine efﬁcacy. Bull World Health Organ 1985;63(6):1055–68.
16] Otter A, Pow I, Reid HW.  Outbreak of malignant catarrhal fever in Welsh Black
cattle in Carmarthenshire. Vet Rec 2002;151(11):321–4. Available at: http://
www.ncbi.nlm.nih.gov/pubmed/12356235.
17] Parameswaran N, Russell GC, Bartley K, Grant DM,  Deane D, Todd H, et al. The
effect of the TLR9 ligand CpG-oligodeoxynucleotide on the protective immune
response to alcelaphine herpesvirus-1-mediated malignant catarrhal fever in
cattle. Vet Res 2014;45(1):59. Available at: http://www.pubmedcentral.nih.
gov/articlerender.fcgi?artid=4059458&tool=pmcentrez&rendertype=abstract
[Accessed 19 December 2014].
18] Penny CD. Clinical refresher-Malignant catarrhal fever. UK Vet 2005;10(5):1–3.
19] Plowright W.  Studies on malignant catarrhal fever of cattle. University of Pre-
toria; 1964.
20] Plowright W.  Malignant catarrhal fever in East Africa: behaviour of the virus in
free-living populations of blue wildebeest (Gorgon taurinus taurinus, Burchell).
Res Vet Sci 1965;6:56–83.
21] Plowright W.  Malignant catarrhal fever. J Am Vet Med Assoc 1968;152(6):
795–805.
22] Plowright W,  Ferris RD, Scott GR. Blue wildebeest and the aetiological agent of
bovine malignant catarrhal fever. Nature 1960;188:1167–8.
23] Plowright W,  Herniman KAJ, Jesset DM,  Kalunda M,  Rampton CS. Immunisa-
tion of cattle against the herpesvirus of malignant catarrhal fever: failure of
inactivated culture vaccines with adjuvant. Res Vet Sci 1975;19:159–66.
24] Radley DE, Young AS, Brown CGD, Burridge MJ,  Cunningham MP, Musisi FL,
et  al. East Coast fever: 2. Cross-immunity trails with a Kenyan strain of Theileria
lawrencei. Vet Parasitol 1975;1:43–50.
25] Reid RS. Savannahs of our Birth. Los Angeles: University of California Press;
2012.
26] Reid HW,  Buxton D, Berrie E, Pow I, Finlayson J. Malignant catarrhal fever. Vet
Rec 1984;114:582–4.
27] Roizmann B, Desrosiers RC, Fleckenstein B, Lopez C, Minson AC, Stud-
dert MJ. The family of Herpesviridae: an update. The Herpesvirus Study
Group of the International Committee on Taxonomy of Viruses. Arch Virol
1992;123:425–49.
28] Rossiter PB, Jessett DM,  Mushi EZ. Antibodies to malignant catarrhal fever virus
antigens in the sera of normal and naturally infected cattle in Kenya. Res Vet
Sci 1980;29:235–9.
29] Rossiter PB, Jessett DM,  Karstad L. Role of wildebeest fetal membranes
and ﬂuids in the transmission of malignant catarrhal fever virus. Vet Rec
1983;113:150–2.
30] Russell GC, Stewart JP, Haig DM.  Malignant catarrhal fever: a review. Vet J
(London, England: 1997) 2009;179(3):324–35.
31] Russell GC, Benavides J, Grant D, Todd H, Deane D, Percival A, et al. Dura-
tion of protective immunity and antibody responses in cattle immunised
against alcelaphine herpesvirus-1-induced malignant catarrhal fever.
Vet Res 2012;43(1):51. Available at: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=3425131&tool=pmcentrez&rendertype=abstract
[Accessed 6 June 2014].
32] Simon S. The vascular lesions of a cow and bison with sheep-associated malig-
nant catarrhal fever contain ovine herpesvirus 2-infected CD8+ T lymphocytes.
J  Gen Virol 2003;84(8):2009–13. Available at: http://vir.sgmjournals.org/cgi/
doi/10.1099/vir.0. 19048-0 [Accessed 19 May  2013].
33] Team, R.C., 2013. R: A language and environment for statistical computing. R
Foundation for Statistical Computing. Available at: http://www.r-project.org/.
34] Thonur L, Russell GC, Stewart JP, Haig DM.  Differential transcription of ovine
herpesvirus 2 genes in lymphocytes from reservoir and susceptible species.
Virus Genes 2006;32(1):27–35. Available at: http://www.ncbi.nlm.nih.gov/
pubmed/16525732 [Accessed 27 March 2013].
35] Meteyer CU, Gonzales BJ, Heuschele WP,  Howard EB. Epidemiologic and patho-
logic aspects of an epizootic of malignant catarrhal fever in exotic hoofstock. J
Wildlife Dis 1989;25(2):280–6.
36] Whitaker KA, Wessels ME,  Campbell I, Russell GC. Outbreak of
wildebeest-associated malignant catarrhal fever in Ankole cattle. Vet
Rec  2007;161:692–5.
37] Cook A. Wildlife-livestock-human interface: recognising drivers of disease. In:
Livestock Systems and Environment Monthly Seminar Series. Nairobi: Interna-38] Lankester F, Lugelo A, Mnyambwa N, Keyyu J, Kazwala R, Grant D, et al. The efﬁ-
cacy of alcelaphine herpesvirus-1 (AlHV-1) immunization with the adjuvants
Emulsigen®  and the monomeric TLR5 ligand FliC in zebu cattle against AlHV-1
malignant catarrhal fever induced by experimental virus challenge.
